Vilon
The simplest Khavinson bioregulator, a synthetic Lys-Glu dipeptide studied for immune modulation and healthy aging.
Vilon is a synthetic dipeptide (lysine-glutamic acid, KE) and the shortest member of Vladimir Khavinson's short-peptide bioregulator catalog, developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a minimal-sequence successor to the thymus extracts Thymalin and Thymogen. It is positioned as a thymic and immune bioregulator proposed to support T-cell maturation, NK-cell activity, and the immune decline that accompanies aging. Evidence is largely Khavinson-group preclinical rodent data plus small, mostly open-label Russian human cohort studies; independent Western replication is limited. Vilon is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound.
Class
Synthetic dipeptide bioregulator (Khavinson class)
Half-life
Not established
Routes
Oral (capsule), Subcutaneous, Intramuscular
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Age-related immune support (immunosenescence)
Vilon is proposed to support residual thymic output and T-cell maturation in older adults, mitigating the naive T-cell decline and reduced immune competence of aging. Khavinson-group observational studies report modest, weak-to-moderate signals rather than transformative changes.
T-cell and cytokine modulation
The Khavinson literature attributes to Vilon modulation of peripheral T-cell subsets (CD4, CD8, CD4/CD8 ratio) and Th1/Th2 balance, plus normalization of cytokine production via proposed epigenetic gene regulation in immune-related pathways.
Natural killer cell activity
Vilon is claimed to support NK-cell cytotoxicity relevant to anti-viral and anti-cancer immune surveillance, part of its positioning as a broad-spectrum immune modulator in aging subjects.
Thymocyte proliferation (preclinical)
In mouse thymocyte cultures, Vilon produced the most potent comitogenic stimulation of thymocyte proliferation and sphingomyelinase activity among the peptides tested, providing mechanistic evidence for thymopoiesis-promoting activity.
Longevity / anti-aging exploration
Preclinical rodent studies from the Khavinson group have reported lifespan extension (24–42% in some models) and reduced tumor incidence; human cohort data on hard outcomes are not available in controlled form, so longevity benefit in humans is genuinely unknown.
Mechanism
How it works
Vilon is the minimal active dipeptide unit of the Khavinson thymic bioregulator class, isolated as the low-molecular-weight immunomodulatory component of thymalin. Being just two peptide-bond-linked residues (lysine, positively charged; glutamate, negatively charged), it is proposed to be small enough (~261–275 Da) to be absorbed intact across the intestinal epithelium and to enter cells and cell nuclei without active transport.
The Khavinson framework proposes that Vilon acts through sequence-selective DNA binding: that a two-residue ligand can still make enough electrostatic and hydrogen-bonding contacts with specific DNA regulatory regions to influence transcription at particular promoters, producing tissue-selective gene expression. Vilon's extreme structural simplicity makes it the cleanest reference test case for this model, which is foundational to Khavinson's theory but a stronger assertion than mainstream Western molecular biology accepts.
At the cellular level, Vilon is proposed to modulate intracellular signaling in thymocytes, including sphingomyelin pathway signal transduction, thereby restoring T-cell activation thresholds and proliferative responses in immune cells from elderly subjects. The Lys-Glu sequence is also the structural core of longer Khavinson peptides such as the tripeptides Testagen and Vesugen (Lys-Glu-Asp) and the tetrapeptide Pancragen (Lys-Glu-Asp-Trp).
Overall, the mechanism is best characterized as proposed rather than established: preclinical rodent and in vitro data suggest real biological activity on thymocyte proliferation and immune markers, but the tissue-selective transcriptional mechanism has not been rigorously validated by independent Western laboratories.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Oral capsules require no reconstitution; the commercial 20 mg capsule contains ~2–4 mg of peptide in milk-protein and starch excipients and is swallowed whole on an empty stomach. For injectable research-chemical use: reconstitute lyophilized peptide with bacteriostatic water (0.9% benzyl alcohol). A typical 10 mg vial reconstituted with 2 mL yields 5 mg/mL (5000 mcg/mL), so 50 mcg = 0.01 mL (1 unit on a U-100 insulin syringe), 100 mcg = 0.02 mL (2 units), 200 mcg = 0.04 mL (4 units). Trickle the water down the vial wall, swirl gently (do not shake), refrigerate reconstituted solution at 2–8°C and use within 14–30 days.
Beginner (oral)
- Dose
- 1 capsule (20 mg nominal, ~2–4 mg peptide)
- Frequency
- Once daily for 10 consecutive days
- Timing
- Morning on an empty stomach with water, 15–30 min before food
- Duration
- 10-day cycle, then 60–90 day washout; up to 2 cycles in the first year
- Route
- Oral
Establish baseline labs and vaccination status first; run Vilon as a solo new variable and keep a daily energy/wellbeing/infection log.
Intermediate (oral)
- Dose
- 2 capsules (40 mg nominal, ~4–8 mg peptide)
- Frequency
- Daily, split morning and early afternoon, for 10 consecutive days
- Timing
- Empty stomach, morning and early afternoon
- Duration
- 10-day cycle, 60–90 day washout; up to 3 cycles per year
- Route
- Oral
For users who tolerated an initial cycle; may rotate other Khavinson peptides across cycles (e.g. Epitalon, Pinealon) and maintain an evidence-based baseline immune support stack between cycles.
Advanced (oral)
- Dose
- 2–3 capsules (40–60 mg nominal, ~4–12 mg peptide)
- Frequency
- Daily, split morning and afternoon, for 10 consecutive days
- Timing
- Empty stomach, split dosing
- Duration
- 10-day cycle, 60–90 day washout; up to 4 cycles per year
- Route
- Oral
No dose-ranging data supports oral dosing above 2 capsules; forum reports suggest no consistent additional benefit at higher doses. Only for experienced users with defined benefit thresholds and clinician oversight.
Injectable (research-chemical)
- Dose
- 50–200 mcg
- Frequency
- Once daily during cycle
- Timing
- Morning, subcutaneous into abdomen or thigh fat
- Duration
- 10–20 day cycle, standard 60–90 day washout
- Route
- Subcutaneous
Research-chemical territory; evidence does not show injectable is superior to oral for any measurable outcome. Never inject IM/IV, never mix with another peptide in the same syringe, use a U-100 insulin syringe.
- The 20 mg capsule label refers to total powder, not peptide dose; actual peptide content is approximately 2–4 mg per capsule.
- Cycling convention is 10-days-on / 60-to-90-days-off, a Khavinson tradition rather than a pharmacokinetically validated schedule; most users do 2–4 cycles per year.
- Dosing is not differentiated by immune goal (immunosenescence support vs. post-illness recovery vs. general anti-aging) — the same 1–2 capsules daily for 10 days is used regardless.
- Oral bioavailability is thought to be modestly better on an empty stomach; taking with food reduces peak concentration but does not eliminate absorption.
- Missed doses during a cycle: skip and resume the next day, do not double up; a cycle interrupted by more than 2 missed days is best terminated and restarted fresh after washout.
- Vilon is oriented to older adults with age-related immune concerns; younger adults (under 40) without specific indications generally do not need it. It should be layered onto vaccination, lifestyle, and chronic-disease control, not used as a primary immune strategy.
Evidence
Research & clinical studies (2)
Comparative study of the effects of vilon, epithalon, and cortagen on thymocyte proliferation and sphingomyelinase activity
In mouse thymocyte cultures, vilon produced the most potent comitogenic stimulation of thymocyte proliferation and sphingomyelinase activity compared with epithalon and cortagen, supporting a thymopoiesis-promoting mechanism relevant to immune restoration in aging.
PMID 12420072Immunomodulatory peptides from the thymus
Describes the isolation of vilon (Lys-Glu) as the active immunomodulatory dipeptide from thymalin, documenting its activation of T-cell differentiation and cytokine regulatory activity and establishing it as the low-molecular-weight component responsible for thymalin's immune-modulating and geroprotective properties.
PMID 9637345Combinations
Stacking & blends
Vilon + Thymogen (immune rotation)
Broad thymic/immune support in aging
Both are short Khavinson thymic-immune peptides with overlapping but distinct proposed gene targets; the common convention is to run them as alternating cycles rather than concurrently, as concurrent use has no trial evidence over single-compound cycling.
Vilon + Epitalon (pineal-thymic axis)
Anti-aging via Khavinson's pineal-thymic model
Epitalon is proposed to act on the pineal gland (circadian, telomerase) while Vilon acts on the thymus (immune, T-cell); the paired-axis framing targets both proposed interlocked drivers of systemic aging.
Khavinson multi-axis rotation
Distribute bioregulator exposure across immune, pineal, and cognitive axes over a year
A common intermediate rotation cycles Vilon (immune), then Epitalon (pineal/circadian), then Pinealon (cognitive), then Vilon again, spreading bioregulator exposure across three cardinal axes; self-experimental and lacking randomized support.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and breastfeeding
- Known hypersensitivity to short-peptide bioregulators or capsule excipients (milk-protein isolates, starch)
- Active autoimmune disease on biologic or DMARD therapy
- Active hematologic or solid cancer under treatment; active immune checkpoint inhibitor therapy
- Active post-transplant immunosuppression
- Active acute infection requiring medical treatment
- The week before and after any scheduled surgery
- Children and adolescents
Vilon is described as exceptionally well tolerated at the microgram-to-milligram doses used, consistent with its structural simplicity (a dipeptide of two standard dietary amino acids). Serious adverse events are not documented, but the evidence base is small and short-term. The oral excipient matrix contains milk-protein isolates and starch, relevant to those with milk allergy or lactose intolerance. Avoid combining with immunosuppressants, biologics, checkpoint inhibitors, or chemotherapy due to theoretical interference with intended immunosuppression. Separate cycling from vaccination by at least one week in either direction. Long-term safety beyond a year or two of repeated cycling is not documented.
FAQ
Vilon — common questions
What is Vilon?
Vilon is a synthetic Lys-Glu dipeptide (KE) and the shortest peptide in Vladimir Khavinson's short-peptide bioregulator catalog, developed in the late 1990s as a minimal-sequence successor to the thymus extracts Thymalin and Thymogen. It is positioned as a thymic and immune bioregulator for age-related immune decline and is sold as a research-use-only compound, not FDA-approved.
What is Vilon claimed to do for immune function?
It is claimed to support residual thymic output in older adults, modulate peripheral T-cell subsets and Th1/Th2 balance, and support natural killer cell cytotoxicity relevant to anti-viral and anti-cancer surveillance. Reported effect sizes are modest and the studies are small and mostly without placebo controls.
What is the standard Vilon cycle and dose?
The standard Khavinson-framework cycle is 1–2 oral capsules (20 mg nominal each, ~2–4 mg peptide) daily on an empty stomach for 10 consecutive days, followed by a 60–90 day washout, at 2–4 cycles per year. Injectable research-chemical use is sometimes 50–200 mcg subcutaneously daily during a cycle, but oral capsule use is the more conservative choice.
Does Vilon actually work?
Probably a little, for some users, some of the time. The Khavinson literature reports modest immune-marker changes and good tolerability over decades, and preclinical rodent data suggest biological activity, but the studies are small, single-center, mostly open-label, and largely from one research group, with limited independent Western replication. It should be treated as an experimental adjunct, not a primary immune strategy.
Is Vilon the same as Thymalin?
No. Vilon is a synthesized single-sequence Lys-Glu dipeptide, while Thymalin is a multi-component polypeptide extract from bovine thymus tissue. Both target immune function but through different molecular forms; Vilon was in fact isolated as the active low-molecular-weight dipeptide component of thymalin.
Can Vilon extend lifespan or slow aging?
Preclinical rodent studies from the Khavinson group have reported lifespan extension (24–42% in some models) and reduced tumor incidence, but these are methodologically sensitive and not independently replicated in large Western labs. Human data on hard outcomes such as mortality are not available in controlled form, so lifespan benefit in humans is genuinely unknown.
Who should not take Vilon?
Absolute contraindications include pregnancy, breastfeeding, known hypersensitivity, active critical illness, active cancer on treatment, checkpoint inhibitor therapy, post-transplant immunosuppression, active autoimmune disease on biologics, active acute infection, and the perioperative week. It is not intended for children or adolescents, and anyone on biologics or DMARDs should consult their specialist before cycling.
Is Vilon legal?
Vilon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, UK, Canada, or Australia. There is no active FDA approval pathway for Vilon.
